Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia

M. Kalaycio, L. Rybicki, B. Pohlman, R. Dean, J. Sweetenham, S. Andresen, R. Sobecks, M. A. Sekeres, A. Advani, S. Brown, B. Bolwell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH >330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH >330 U/l had active disease. However, when patients in CR were excluded, LDH >330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95% confidence interval 1.41-5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.

Original languageEnglish (US)
Pages (from-to)753-758
Number of pages6
JournalBone Marrow Transplantation
Volume40
Issue number8
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

L-Lactate Dehydrogenase
Acute Myeloid Leukemia
Siblings
Bone Marrow
Transplants
Survival
Cytogenetics
Confidence Intervals

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. / Kalaycio, M.; Rybicki, L.; Pohlman, B.; Dean, R.; Sweetenham, J.; Andresen, S.; Sobecks, R.; Sekeres, M. A.; Advani, A.; Brown, S.; Bolwell, B.

In: Bone Marrow Transplantation, Vol. 40, No. 8, 01.10.2007, p. 753-758.

Research output: Contribution to journalArticle

Kalaycio, M, Rybicki, L, Pohlman, B, Dean, R, Sweetenham, J, Andresen, S, Sobecks, R, Sekeres, MA, Advani, A, Brown, S & Bolwell, B 2007, 'Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia', Bone Marrow Transplantation, vol. 40, no. 8, pp. 753-758. https://doi.org/10.1038/sj.bmt.1705811
Kalaycio, M. ; Rybicki, L. ; Pohlman, B. ; Dean, R. ; Sweetenham, J. ; Andresen, S. ; Sobecks, R. ; Sekeres, M. A. ; Advani, A. ; Brown, S. ; Bolwell, B. / Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. In: Bone Marrow Transplantation. 2007 ; Vol. 40, No. 8. pp. 753-758.
@article{7e74c11fb2664b76bac65d387234360f,
title = "Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia",
abstract = "Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH >330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH >330 U/l had active disease. However, when patients in CR were excluded, LDH >330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95{\%} confidence interval 1.41-5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.",
author = "M. Kalaycio and L. Rybicki and B. Pohlman and R. Dean and J. Sweetenham and S. Andresen and R. Sobecks and Sekeres, {M. A.} and A. Advani and S. Brown and B. Bolwell",
year = "2007",
month = "10",
day = "1",
doi = "10.1038/sj.bmt.1705811",
language = "English (US)",
volume = "40",
pages = "753--758",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia

AU - Kalaycio, M.

AU - Rybicki, L.

AU - Pohlman, B.

AU - Dean, R.

AU - Sweetenham, J.

AU - Andresen, S.

AU - Sobecks, R.

AU - Sekeres, M. A.

AU - Advani, A.

AU - Brown, S.

AU - Bolwell, B.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH >330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH >330 U/l had active disease. However, when patients in CR were excluded, LDH >330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95% confidence interval 1.41-5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.

AB - Prognostic factors for survival following allogeneic BMT for AML include age, disease status and cytogenetic risk classification. Lactate dehydrogenase (LDH) levels have not been studied as a potential risk factor. We reviewed our experience with BMT for AML and included LDH at the time of admission in an analysis of prognostic factors for survival. We found that LDH >330 U/l (1.5 times the upper limit of normal at our institution), older age, active disease, peripheral stem cell graft and male-to-male transplant were significant adverse predictors of survival. After accounting for LDH, other factors such as disease status and cytogenetics were not significantly associated with the outcome of BMT. All but one patient with an LDH >330 U/l had active disease. However, when patients in CR were excluded, LDH >330 U/l remained a significant adverse predictor of overall survival (hazard ratio 2.70, 95% confidence interval 1.41-5.16, P=0.003). We conclude that LDH is an important adverse risk factor for survival and should be included in future studies of risk performed on larger patient cohorts.

UR - http://www.scopus.com/inward/record.url?scp=34948818146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948818146&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705811

DO - 10.1038/sj.bmt.1705811

M3 - Article

C2 - 17700600

AN - SCOPUS:34948818146

VL - 40

SP - 753

EP - 758

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -